Literature DB >> 19211071

[Evaluation of the quality of life of patients with localizad prostate cancer: validation of the Spanish version of the EPIC].

Montse Ferrer1, Olatz Garin, Joan Pera, Josep Maria Prats, Joan Mendivil, Jordi Alonso, Belén De Paula, Ismael Herruzo, Asunción Hervas, Víctor Macias, Alfonso Mariño, María José Ortiz, Sergio Pastor, Javier Ponce De León, Gemma Sancho.   

Abstract

BACKGROUND AND
OBJECTIVE: The EPIC (Expanded Prostate Cancer Index Composite) is a specific questionnaire for patients with prostate cancer designed to evaluate the impact of treatments on their quality of life. It contains 50 items divided in 4 summaries: urinary, intestinal, sexual and hormonal. The objective was to adapt the EPIC to Spanish and to evaluate its metric characteristics.
METHOD: The method followed for the adaptation included translation and back-translation. The metric characteristics were evaluated in 50 patients from each treatment -prostatectomy, brachytherapy and external radiotherapy-, all of whom were administered the EPIC, SF-36 and FACT (Functional Assessment of Cancer Therapy) pre and post intervention. Reliability was evaluated with the Cronbach alpha coefficient. Construct validity was assessed by means of correlations between subscales of the EPIC and questionnaires, and comparing the patients with and without hormonal therapy (T-test). In order to value sensitivity to change, the standardized effect size was calculated after the intervention.
RESULTS: The Cronbach's alpha of the EPIC summaries was high (0.66-0.89). The correlations between the EPIC and the FACT were near or higher than 0.4. Differences were found in the hormonal and sexual summaries between the patients with and without hormonal therapy (p<0.01). The standardized effect size was large (>0.8) in the urinary (3 groups) and sexual (group of prostatectomy) summary, and moderate in the intestinal summary (0.6 and 0.7) for the 2 groups of radiotherapy.
CONCLUSIONS: The Spanish version of the EPIC is reliable, valid and presents an excellent sensitivity to change, being a useful tool to compare the impact in the quality of life of the 3 treatments.

Entities:  

Mesh:

Year:  2009        PMID: 19211071     DOI: 10.1016/j.medcli.2008.01.001

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  10 in total

1.  Development and Validation of Crosswalks for Patient-reported Sexual and Urinary Outcomes Between Commonly Used Instruments.

Authors:  Karandeep Singh; Amy L Tin; Rodney L Dunn; Tae Kim; Andrew J Vickers
Journal:  Eur Urol       Date:  2018-12-17       Impact factor: 20.096

2.  Spanish researchers at the forefront of clinical investigation: the case of quality of life in prostate cancer.

Authors:  Ferran Guedea; Montse Ferrer
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

3.  Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS).

Authors:  Mónica Avila; Yolanda Pardo; Manel Castells; Ferran Ferrer; Ana Boladeras; Joan Pera; Pedro J Prada; Benjamin Guix; Belen de Paula; Helena Hernandez; Angels Pont; Jordi Alonso; Olatz Garin; Karen Bremner; Murray Krahn; Montse Ferrer
Journal:  Qual Life Res       Date:  2014-05-01       Impact factor: 4.147

4.  Study design and protocol for a culturally adapted cognitive behavioral stress and self-management intervention for localized prostate cancer: The Encuentros de Salud study.

Authors:  Frank J Penedo; Michael H Antoni; Patricia I Moreno; Lara Traeger; Dolores Perdomo; Jason Dahn; Gregory E Miller; Steve Cole; Julian Orjuela; Edgar Pizarro; Betina Yanez
Journal:  Contemp Clin Trials       Date:  2018-07-09       Impact factor: 2.226

5.  Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment.

Authors:  Kyung Jin Chung; Jung Jun Kim; Soo Hyun Lim; Tae Heon Kim; Deok Hyun Han; Sung Won Lee
Journal:  Korean J Urol       Date:  2010-09-16

6.  Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.

Authors:  Éric Vigneault; Josée Savard; Marie-Hélène Savard; Hans Ivers; Philippe Després; William Foster; André-Guy Martin; Vincent Fradet
Journal:  Can Urol Assoc J       Date:  2017-11-01       Impact factor: 1.862

7.  Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study.

Authors:  Evelyn Martínez; Olatz Garin; Yolanda Pardo; Pablo Fernández; Benjamin Guix; Cristina Gutiérrez; Ana Boladeras; Ferran Ferrer; Tania Hernández; Adriana Ayala; Mikel Egiguren; Gema Fernández; Víctor Muñoz; Víctor Macías; Joan Pera; Àngels Pont; Montserrat Ferrer; Ferran Guedea
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

8.  Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.

Authors:  Alan Katz; Montserrat Ferrer; José Francisco Suárez
Journal:  Radiat Oncol       Date:  2012-11-20       Impact factor: 3.481

9.  The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.

Authors:  Martin H Umbehr; Lucas M Bachmann; Cedric Poyet; Peter Hammerer; Johann Steurer; Milo A Puhan; Anja Frei
Journal:  Health Qual Life Outcomes       Date:  2018-02-20       Impact factor: 3.186

10.  Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer.

Authors:  Antonio Lazo; Alejandro de la Torre-Luque; Gregorio Arregui; Daniel Rivas; Ana Serradilla; Joaquin Gómez; Francisca Jurado; María Isabel Núñez; Escarlata López
Journal:  Biology (Basel)       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.